XML 57 R47.htm IDEA: XBRL DOCUMENT
v3.23.1

DIVENSTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Feb. 28, 2023 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022
Licensing Arrangements [Line Items] |  |  |  |
Proceeds from divestiture of businesses, net of cash divested |  | $ 220 | $ 397 |
Divestiture gain |  | 0 | 211 |
Nimbus Therapuetics TYK2 Inhibitor |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Proceeds from legal settlements |  | 400 |  | $ 40
Contingent sales-based milestones | $ 2,000 |  |  |
Other (income)/expense |  | 400 |  |
Immatics |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Upfront payments |  |  | 150 |
Contingent and regulatory milestone payments |  |  | 770 |
Dragonfly |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Upfront payments |  |  | 175 |
Nimbus Therapeutics |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Upfront payments | $ 4,000 |  |  |
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Change in control proceeds |  |  |  | 10.00%
Percentage of ownership acquired | 100.00% |  |  |
Mature products and other |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Proceeds from divestiture of businesses, net of cash divested |  | 4 | 225 |
Divestiture gain |  | $ 0 | 211 |
Mature products and other | Cheplapharm |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |
Proceeds from divestiture of businesses, net of cash divested |  |  | $ 221 |

X
- Definition Asset Acquisition, Percentage of Ownership Acquired + References No definition available. + Details
Name: | bmy_AssetAcquisitionPercentageOfOwnershipAcquired
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement Contingent Payments Maximum Exposure + References No definition available. + Details
Name: | bmy_CollaborativeArrangementContingentPaymentsMaximumExposure
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent and Regulatory Milestone Payments + References No definition available. + Details
Name: | bmy_ContingentAndRegulatoryMilestonePayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License and Other Arrangements Upfront Payments + References No definition available. + Details
Name: | bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Licensing Arrangements + References No definition available. + Details
Name: | bmy_LicensingArrangementsLineItems
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Settlement, Contingent Development, Change In Control Proceeds + References No definition available. + Details
Name: | bmy_SettlementContingentDevelopmentChangeInControlProceeds
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income related to nonoperating activities, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherNonoperatingIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the cash inflow during the period from the sale of a component of the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received for the settlement of litigation during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_NimbusTherapueticsTYK2InhibitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_ImmaticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_DragonflyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_NimbusTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_MatureBrandsAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_CheplapharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |